XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Buys 1,000 Shares of Stock

XOMA Co. (NASDAQ:XOMA – Get Rating) CIO Bradley Sitko acquired 1,000 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The shares were purchased at an average price of $19.50 per share, with a total value of $19,500.00. Following the completion of the transaction, the executive now owns 3,000 shares of the company’s stock, valued at approximately $58,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bradley Sitko also recently made the following trade(s):

• On Monday, May 15th, Bradley Sitko purchased 1,500 shares of XOMA stock. The stock was purchased at an average cost of $23.40 per share, with a total value of $35,100.00.
• On Friday, May 12th, Bradley Sitko purchased 2,000 shares of XOMA stock. The shares were purchased at an average cost of $18.99 per share, for a total transaction of $37,980.00.

XOMA Stock Performance

NASDAQ:XOMA opened at $19.41 on Tuesday. XOMA Co. has a 52 week low of $15.68 and a 52 week high of $32.08. The stock’s fifty day moving average is $19.74 and its two-hundred day moving average is $20.08.

XOMA (NASDAQ:XOMA – Get Rating) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.62 million. XOMA had a negative return on equity of 20.65% and a negative net margin of 774.65%. Equities research analysts predict that XOMA Co. will post -1.44 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

A number of hedge funds have recently added to or reduced their stakes in XOMA. UBS Group AG increased its position in shares of XOMA by 9,318.8% during the third quarter. UBS Group AG now owns 1,507 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 1,491 shares during the period. Bank of America Corp DE increased its holdings in XOMA by 40.7% during the 4th quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 689 shares during the period. Tower Research Capital LLC TRC raised its position in XOMA by 1,479.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,017 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,826 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of XOMA by 81.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,449 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,102 shares during the period. Finally, Natixis acquired a new position in shares of XOMA during the fourth quarter worth about $66,000. 54.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. StockNews.com assumed coverage on XOMA in a research note on Thursday, May 18th. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $69.00 target price on shares of XOMA in a research note on Friday, March 10th. Finally, TheStreet cut shares of XOMA from a “c” rating to a “d” rating in a research report on Thursday, March 30th.

XOMA Company Profile

(Get Rating)

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.